We found that CM patients in the low-cTMGs group had a significantly higher response to ACT, MAGE-A3 antigen-specific cancer immunotherapy, anti-PD-1 monotherapy, or anti-PD-1/anti-CTLA-4 combined therapy compared with those in the high-cTMGs group. Here, PDCD1 is linked to cancer.